Bibicoff + MacInnis to Implement Investment Community Outreach Program
SAN DIEGO--(BUSINESS WIRE)-- Entest BioMedical Inc. (OTCQB: ENTB), a veterinary biotechnology company and operator of veterinary hospitals, today announced that it has engaged Bibicoff + MacInnis, Inc., a full service investor relations and strategic planning firm, to increase investment community awareness of the Company. Bibicoff + MacInnis will initially concentrate on developing and implementing communications strategies and programs specifically targeting the retail brokerage, institutional and investment banking communities.
Harvey Bibicoff, President and CEO of Bibicoff + MacInnis, stated, "Entest BioMedical is creating a business which, in concept, has a biotech upside wrapped around a revenue generating, cash flow generating business. Veterinary hospitals comprise the business component. The development of veterinary therapies is the biotech component. This concept, in this industry, has been shown to be enormously successful.
“Entest understands that current and accurate stockholder communications is critical in developing shareholder interest and loyalty. We expect that as the Company's management successfully implements its growth-oriented business strategy, that Wall Street will appreciate the business model, future outlook, and growth potential and reward ENTB with significant and long-term market support,” Bibicoff concluded.
Entest BioMedical has two veterinary therapeutic treatments currently undergoing testing. The first, ImenVaxTM, is an immuno-therapeutic cancer vaccine for canines. Three dogs in the 10 dog study have currently been dosed with promising early results. For the second treatment, the Company is the contract research organization for an ongoing pilot study for the treatment of canine osteoarthritis. Entest BioMedical will have the right to use the stem cell based treatment in its clinics once it has been approved.
The Company recently announced its relationship with Emerald Valley Pet Medical Center in Eugene, Oregon. This represents the second veterinary hospital producing revenue for Entest -- creating another distribution channel for the Company’s biotech therapies. The Company expects to continue to add to its network and is targeting several more veterinary hospitals for 2012.
David R. Koos, founder and CEO of Entest BioMedical said, "We believe that now is the appropriate time in the development of our business model to tell the investment community who we are and where we are going. We view the engagement of Bibicoff + MacInnis as an important step in the process of developing accurate communications with the investment community. Accurate and consistent communication is the foundation upon which a strong and liquid market for ENTB stock can be built. As we grow our business, we expect that Bibicoff + MacInnis will be a valuable asset to help guide the Company's activities in the investment banking and investor communications arenas.”
About Entest BioMedical Inc.
Entest BioMedical Inc. (http://www.entb.net/) is a veterinary biotechnology company focused on developing therapies that harness the animal's own reparative / immunological mechanisms. The Company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). ImenVax™ is less invasive and less traumatic in treating cancer. Additionally, the Company serves as the contract research organization conducting a pilot study on a stem cell based canine osteoarthritis treatment (developed by RenovoCyte LLC) utilizing a ‘universal donor’ stem cell. Entest is also building a network of veterinary hospitals (present locations include one in Santa Barbara, CA and another in Eugene, OR) – which serve as distribution channels for its products.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Investor Relations Contact:
Bibicoff + MacInnis, Inc.
Terri MacInnis, Dir. of Investor Relations
Entest BioMedical Inc.
David R. Koos, Chairman and CEO
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Communications Research Public Relations/Investor Relations Veterinary Science